Thu. 14 Mar 2024, 8:06am ET
Benzinga
Earnings, News, Guidance, Health Care, General
Operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million, due primarily to the $2.7 million loss in the DERMAdoctor skincare segment. The dermadoctor skincare segment loss includes a $2.5 million non-cash impairment of goodwill and indefinite lived and long-lived assets related to the business segment